PTC Therapeutics, Inc. PTCT 深 沪
等待开盘 05-12 09:30:00 美东时间
76.85
+2.510
+3.38%
华盛通- 最 高79.91
- 今 开74.88
- 成交量 927.10万股
- 最 低 64.24
- 昨 收 74.34
- 总市值 548.23万
- 52周最高 87.50
- 市盈率 静 --
- 换手率 12995.78%
- 52周最低 43.175
- 委 比 -86.26%
- 总股本 7.13万
- 历史最高 87.50
- 量 比 5.15
- 振 幅 21.08%
- 历史最低 1.10
- 每 手 1
- 风险率 11.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For February 19, 2026
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof
PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.
02-13 19:18
Why Sandisk Shares Are Rallying Monday After Close
Sandisk is joining the S&P 500 Index, prompting a boost in the share price Monday after market close.
2025-11-25 06:59
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-11 20:15
PTC Therapeutics(PTCT)与诺华制药(NVS)签署亨廷顿病药物许可协议
金吾财讯 | 美国生物制药公司PTC Therapeutics(PTCT)与诺华制药(NVS)签署了关于PTC518亨廷顿病项目的独家全球许可和合作协议。PTC518目前正在进行2期PIVOT-HD试验，并显示出良好的安全性和耐受性。根据协议，PTC Therapeutics将获得10亿美元的预付款，高达19亿美元的开发、监管和销售里程碑，在美国的利润分成为40%，并在美国以外的地区获得两位数的销售分层版税。该协议预计将于2025年第一季度完成。
2024-12-02 21:43
2025年美股Biotech有望大涨 摩根大通首选福泰制药
华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司（即Biotech）股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药（VRTX.US）在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下，生物科技类股票可谓是最佳受益于降息周期的股票板块，在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解，在摩根大通最新发布的研报中，该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $64 price target.
2024-09-17 22:37
Baird Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces Price Target of $44
Baird analyst Joel Beatty initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Outperform rating and announces Price Target of $44.
2024-09-04 17:39
ClearPoint Neuro Repays $10 Million Convertible Note Early
04:39 PM EDT, 08/26/2024 (MT Newswires) -- ClearPoint Neuro (CLPT) said Monday that it has made a full early repayment of principal and interest on a $10 million convertible note January 2025 on Friday. The company said the note was held by PTC Therapeutics (PTCT). Shares of the company were up abou...
2024-08-27 04:39
PTC Therapeutics Has Upside Potential With Multiple Upcoming Catalysts, UBS Says
12:17 PM EDT, 08/26/2024 (MT Newswires) -- PTC Therapeutics (PTCT) is positioned for potential upside with several key catalysts on the horizon, UBS said in a note Monday. "With multiple [New Drug Application] filings this year & potential commercial launches next year (PKU, FA, AADC) along with upc...
2024-08-27 00:17
